Every October, the world is awash in pink. From corporate campaigns to charity walks, the month of October, Breast Cancer Awareness Month, reminds us of the importance of screening, early detection, and treatment. Yet, when the pink ribbons fade, the sobering truth remains breast cancer doesn’t wait for October.
Across the world, every two minutes, a woman is diagnosed with breast cancer. In Nigeria, the statistics are even more alarming, too many women still present at late stages of the disease when treatment options are limited and survival rates are drastically reduced. The major reason? Late presentation and lack of access to early diagnostic tools and tailored treatment approaches.
In my work at Biologix Support Services, we see firsthand how critical timing is. Cancer does not pause while we deliberate or delay testing. Unfortunately, many Nigerian women still rely heavily on prayer, self-medication in the form of herbal treatment, or outdated information, only seeking medical help when cancer has advanced to late stages. This pattern leads to avoidable loss of life.
But beyond timing, the other critical piece we must address is how we treat breast cancer. For too long, the standard approach, chemotherapy, radiotherapy, or surgery, has been applied as a one-size-fits-all model. These treatments, though lifesaving in many cases, can also be harsh and sometimes ineffective, especially when the cancer behaves differently from what was expected.
This is where precision medicine, or personalized medicine, changes the game.
Precision medicine recognizes that every cancer is unique. It uses advanced genomic testing to identify the specific characteristics and mutations of a person’s cancer cells. This allows doctors to tailor treatment precisely to that individual, targeting the cancer’s weaknesses while minimizing harm to healthy cells.
Think of it as the difference between using a sledgehammer and using a scalpel. Traditional chemotherapy often attacks both healthy and cancerous cells, leading to severe side effects. Precision medicine, on the other hand, focuses treatment like a laser beam on the specific mutation driving the cancer.
For example, breast cancer has different subtypes, some are hormone-driven (estrogen, progesterone or HER2 positive), others may be driven by certain mutations like BRCA 1 and BRCA 2 gene mutations. Knowing this difference allows us to choose therapies that specifically block those hormones or target other genetic changes in the tumor. In some cases, this approach can even minimize or eliminate the need for chemotherapy altogether.
The promise of precision medicine is already being realized globally, but Africa, and Nigeria in particular, has lagged behind due to limited infrastructure, high costs, and a shortage of professionals trained in genomics and bioinformatics.
At Biologix, we identified this gap and took steps to close it. We established one of the first private genomics laboratories in Nigeria, providing access to molecular and genetic profiling for cancers such as breast, ovarian, prostate, and lung cancer. This means patients no longer need to send samples abroad for testing, a process that’s often too slow and too expensive for many families.
We also work closely with oncologists, pharmaceutical companies, and teaching hospitals to educate both doctors and patients on how genomic testing can improve outcomes. In one of our recent lung cancer studies, patients identified with specific mutations were able to access targeted drugs from our pharma partner companies, and many of them showed remarkable recovery.
The success of precision medicine depends on one thing above all else, early diagnosis. Cancer patients do not have the luxury of time. By the time symptoms become visible or painful, the disease is often advanced. Nigerians must begin to see preventive healthcare as a necessity, not a luxury.
Government and private institutions must also play their part by integrating genomic testing into the national cancer care framework and supporting research into African genetic profiles. For pharmaceutical companies, this is the time to invest in partnerships that make targeted therapies more affordable and accessible.
Breast cancer is not a death sentence, especially when detected early and treated with the right approach. Precision medicine offers us a pathway to make treatment more effective, humane, and hopeful. But awareness must go beyond pink ribbons and hashtags. It must translate into access, education, and empowerment.
We owe it to every woman, and every family affected, to ensure that when breast cancer strikes, they have more than one path to survival.
Dr. Voke Toye is the Founder and CEO of Biologix Support Services, a pioneering genomics and bioinformatics company dedicated to advancing precision medicine and improving cancer treatment outcomes in Nigeria.
